PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

@article{Majewski2015PIK3CAMA,
  title={PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.},
  author={Ian J. Majewski and Paolo Nuciforo and Lorenza Mittempergher and Astrid Bosma and Holger Eidtmann and Eileen Holmes and Christos Sotiriou and Debora Fumagalli and Jos{\'e} Jim{\'e}nez and Claudia Monica Aura and Ludmila Prudkin and Maria Carmen D{\'i}az-Delgado and Lorena de la Pe{\~n}a and Sherene Loi and Catherine L Ellis and Nikolaus Schultz and Evandro de Azambuja and Nadia Harbeck and Martine J. Piccart-Gebhart and Ren{\'e} Bernards and Jos{\'e} Baselga},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 12},
  pages={
          1334-9
        }
}
PURPOSE We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2 (HER2) -targeted therapies in patients with breast cancer. PATIENTS AND METHODS Baseline tissue biopsies were available from patients with HER2-positive early breast cancer who were enrolled onto the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial (NeoALTTO… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

BYL 719 , a next generation PI 3 K alpha specific inhibitor : Preliminary safety , PK , and efficacy results from the first - inhuman study

  • D Juric, J Rodon, AM Gonzalez-Angulo
  • Cancer Res
  • 2013

GDC0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study

  • D Juric, I Krop, RK Ramanathan
  • Cancer Res 73:LB-64,
  • 2013
1 Excerpt

matic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

  • K Kalinsky, LM Jacks, A Heguy
  • J Natl Cancer Inst
  • 2013

Similar Papers

Loading similar papers…